AstraZeneca Pharma India has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a profit after tax of ₹623.3 million for the quarter. The half-year period saw a profit after tax of ₹1,002.6 million. The report also includes details on total comprehensive income and earnings per share, alongside key appointments to its board and senior management positions.
| Particulars | Quarter ended 30-09-2026 | Half-year ended 30-09-2026 | Year ended 31-03-2026 | |||
| Unaudited | Unaudited | Unaudited | Unaudited | Audited | ||
| Income | ||||||
| a) Revenue from operations | 7,291.0 | 6,827.9 | 5,590.9 | 14,118.9 | 10,854.0 | 22,755.8 |
| b) Other income | 151.2 | 92.3 | 61.7 | 243.5 | 174.1 | 284.9 |
| Total income | 7,442.2 | 6,920.2 | 5,652.6 | 14,362.4 | 11,028.1 | 23,040.7 |
| Expenses | ||||||
| a) Cost of materials consumed | 94.9 | 94.9 | ||||
| b) Purchase of stock-in-trade | 6,241.0 | 3,046.2 | 4,324.0 | 9,287.2 | 8,499.9 | 18,594.2 |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,502.5) | 1,425.9 | (1,079.1) | (76.6) | (2,395.8) | (4,883.7) |
| d) Employee benefit expense | 678.5 | 791.6 | 604.5 | 1,470.1 | 1,249.0 | 2,643.8 |
| e) Finance costs | 18.9 | 19.5 | 6.7 | 38.4 | 13.9 | 44.9 |
| f) Depreciation and amortisation expense | 53.5 | 52.3 | 25.7 | 105.8 | 191.4 | 285.8 |
| g) Selling, marketing and distribution expense | 177.0 | 307.5 | 280.1 | 484.5 | 500.3 | 1,160.0 |
| h) Other expenses | 741.3 | 767.3 | 709.6 | 1,508.6 | 1,342.8 | 2,526.3 |
| Total expenses | 6,407.7 | 6,410.3 | 4,871.5 | 12,818.0 | 9,496.4 | 20,466.2 |
| 3 Profit before exceptional Items and tax (1-2) | 1,034.5 | 509.9 | 781.1 | 1,544.4 | 1,531.7 | 2,574.5 |
| 4 Add/(Less): Exceptional items (Refer Note 3,4,5) | (149.6) | (2.4) | (52.9) | (152.0) | (56.5) | (52.5) |
| 5 Profit before tax (3+4) | 884.9 | 507.5 | 728.2 | 1,392.4 | 1,475.2 | 2,522.0 |
| 6 Tax expense | ||||||
| a) Current tax | 250.3 | 108.7 | 190.1 | 359.0 | 411.1 | 591.4 |
| b) Tax expense for prior years | 2.8 | |||||
| c) Deferred tax charge / (credit) | 11.3 | 19.5 | (4.1) | 30.8 | (36.4) | 52.6 |
| Total tax expense (net) | 261.6 | 128.2 | 186.0 | 389.8 | 374.7 | 646.8 |
| 7 Profit after tax (5-6) | 623.3 | 379.3 | 542.2 | 1,002.6 | 1,100.5 | 1,875.2 |
| 8 Other comprehensive (loss) / Income | ||||||
| Items that will not be reclassified to profit or loss | ||||||
| a) Re-measurement (losses)/ gains on post employment benefit obligations | (3.7) | (4.0) | (4.1) | (7.7) | 4.1 | (59.4) |
| b) Income tax effect on above | 0.9 | 1.0 | 1.1 | 1.9 | (1.0) | 15.0 |
| Other comprehensive (loss)/ Income,net of income tax | (2.8) | (3.0) | (3.0) | (5.8) | 3.1 | (44.4) |
| 9 Total comprehensive income for the period/ year (7+8) | 620.5 | 376.3 | 539.2 | 996.8 | 1,103.6 | 1,830.8 |
| 10 Paid-up equity share capital (Face value of Rs 2/- per equity share) | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 |
| 11 Other Equity | 8,677.9 | |||||
| 12 Earnings per equity share of Rs 2/- each (basic and diluted) *Not annualised | 24.93* | 15.17* | 21.69* | 40.10* | 44.02* | 75.01 |
Key Appointments and Board Actions
The Board of Directors also approved several key appointments and changes in designations. Mr. Krishnamurthy Narayanan Iyer has been appointed as an Additional Director (Non-Executive, Independent) effective November 5, 2026, for a term of five years. Mr. Atul Tandon has been appointed as the Chief Financial Officer, effective November 9, 2026. Furthermore, Mr. Nitin Bindal‘s designation changed to Director – Biopharmaceuticals Business Unit, also effective November 9, 2026. Mr. Kumaran Krishnan is set to become Medical Director – Biopharmaceuticals Business Unit starting December 1, 2026.
Financial Highlights
For the quarter ended September 30, 2026, AstraZeneca Pharma India reported total income of ₹7,442.2 million and profit after tax of ₹623.3 million. This compares to a profit after tax of ₹379.3 million in the same quarter of the previous year. For the half-year ended September 30, 2026, the company posted total income of ₹14,362.4 million and profit after tax of ₹1,002.6 million. Earnings per share for the quarter stood at ₹24.93 (basic and diluted), and ₹40.10 for the half-year.
Operational Updates
The company also stated that the financial results have been prepared in accordance with Indian Accounting Standards and are in compliance with SEBI regulations. The results have been reviewed by statutory auditors, who have expressed an unmodified review conclusion. The company has also made information available on its website, www.astrazeneca.com/india. The meeting of the Board of Directors commenced at 1:30 p.m. and concluded at 3:50 p.m. on November 5, 2026.
Source: BSE
